Perception Neuroscience’s lead development product is the NMDA antagonist arketamine (PCN-101), a single isomer of ketamine. Arketamine belongs to a new generation of glutamate receptor modulators with the suggested potential for rapid acting antidepressant (RAAD) activity. Most of the currently FDA-approved antidepressant therapies often take weeks to achieve maximal effectiveness. Perception Neuroscience was founded on the...
Perception Neuroscience’s lead development product is the NMDA antagonist arketamine (PCN-101), a single isomer of ketamine. Arketamine belongs to a new generation of glutamate receptor modulators with the suggested potential for rapid acting antidepressant (RAAD) activity. Most of the currently FDA-approved antidepressant therapies often take weeks to achieve maximal effectiveness. Perception Neuroscience was founded on the basis of evidence from animal models of depression as well as safety reports from academic studies in healthy volunteers.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.